Maryann Redlinger
Publications by Year
Research Areas
Autophagy in Disease and Therapy, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, Renal cell carcinoma treatment
Most-Cited Works
- → Phase II Trial of Sorafenib in Advanced Thyroid Cancer(2008)676 cited
- → Combined MTOR and autophagy inhibition(2014)414 cited
- → Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma(2019)148 cited
- → A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel(2008)146 cited
- → Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis(2006)50 cited
- → Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study(2011)49 cited
- → Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma(2005)49 cited
- → Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer(2001)43 cited
- → Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients(2009)32 cited
- → Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors(2009)30 cited